Format

Send to

Choose Destination
Stem Cell Res Ther. 2015 Dec 1;6:234. doi: 10.1186/s13287-015-0240-9.

The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy.

Author information

1
Department of Burns and Cutaneous Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, People's Republic of China.
2
Department of Burn and Plastic Surgery, the 205th Hospital of People's Liberation Army, Jinzhou, Liaoning, 121000, PR China.
3
Changchun Zhongyan Medical Cosmetic Hospital, Changchun, Jilin, 130000, PR China.
4
Department of Plastic Surgery, General Hospital of Shenyang Military Area Command of People's Liberation Army, Shenyang, Liaoning, 110016, PR China.
5
Department Of Neurology, the 303th Hospital of People's Liberation Army, Nanning, Guangxi, 530021, PR China.
6
Department of Burns and Cutaneous Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, People's Republic of China. wangyunchuan@fmmu.edu.cn.
7
Department of Burns and Cutaneous Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, People's Republic of China. hudhai@sohu.com.

Abstract

Mesenchymal stem cells (MSCs) are ideal for cell-based therapy in various inflammatory diseases because of their immunosuppressive and tissue repair properties. Moreover, their immunosuppressive properties and low immunogenicity contribute to a reduced or weakened immune response elicited by the implantation of allogeneic MSCs compared with other cell types. Therefore, implantation of allogeneic MSCs may be a promising cell-based therapy. In this review, we first summarize the unique advantages of allogeneic MSCs for therapeutic applications. Second, we critically analyze the factors influencing their therapeutic effects, including administration routes, detection time-points, disease models, differentiation of MSCs in vivo, and timing and dosage of MSC administration. Finally, current approaches to allogeneic MSC application are discussed. In conclusion, allogeneic MSCs are a promising option because of their low immunogenicity and immunosuppressive and tissue repair capabilities. Further investigations are needed to enhance the consistency and efficacy of MSCs when used as a cell-based therapy in inflammatory diseases as well as for tissue repair.

PMID:
26620426
PMCID:
PMC4665863
DOI:
10.1186/s13287-015-0240-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center